Osteoarthritis Therapeutics Marketplace Reviewed in New Comprehensive GlobalData Report Published at MarketPublishers.com01 Dec 2015 • by Natalie Aster
LONDON – Osteoarthritis (OA) is poised to be the 4th major cause of disability by end-2020.
Forecasts say the total prevalent cases of hand OA will increase to 175,213,683 in the seven major markets (7MM) by 2024, posting an annual growth rate (AGR) of 1.63%. The total number of prevalent cases of knee OA in these markets will likely amount to 127,929,359 in 2024, recording just over 1.55% AGR during the forecasted period. The total prevalent cases of hip OA in the 7MM are likely to increase to 69,699,696, at 1.4% AGR through to 2024.
Meantime, the diagnosed prevalent cases of hand OA in the 7MM are forecast amount to 70,996,375 in 2024, at 1.63% AGR over the forecast period. The diagnosed prevalent cases of knee OA in the 7MM are projected to surge to 43,877,213 by the end of the forecast period, with just under 1.6% AGR through to 2024. The diagnosed prevalent cases of hip OA in the 7MM are projected to rise to 17,276,030 in 2024, with 1.43% AGR from 2014 to 2024.
New comprehensive market research report “EpiCast Report: Osteoarthritis - Epidemiology Forecast to 2024” elaborated by GlobalData presents an in-depth, top-quality, transparent assessment of the trends that have been shaping and propelling the worldwide market for osteoarthritis therapeutics. The research study provides an unbiased, deep review of the risk factors, sheds light on the comorbidities, and also looks into the worldwide and historic trends for hip OA, hand OA and knee OA across the 7MM – the USA, Germany, France, Italy, the UK, Spain and Japan. Furthermore, the research publication is supplemented with granular ten-year epidemiological forecasts for the diagnosed prevalent cases and total prevalent cases of the three disease types, segmented based on sex and age group in the aforementioned markets.
EpiCast Report: Osteoarthritis - Epidemiology Forecast to 2024
Published: November, 2015
Price: US$ 3,995.00
More studies by the publisher can be found at GlobalData page.